Skip to main content

Table 1 Clinical histories of glioma patients

From: Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma

Case ID GBM-1 AA-1 AO-1
Gender M F M
Age at the time of Dx 55 51 58
KPS at the time of Dx 70% 80% 60%
Symptoms Aphasia Seizure Hemi-paresis, seizure
Histology GBM AA AO
Time from Dx to PBMC sampling 24 mos 153 mos 82 mos
Tumor location Lt. hemisphere Lt. temporal lobe Lt. frontal lobe
Treatment Bx Bx Bx, cystic aspiration
  FEBRT FEBRT FEBRT
  TMZ/CPT-11 (7 cycles) BCNU/CDDP/VP-16 (4 cycles) PCV (3 cycles), TMZ
Time to progression from the Dx 3 mos No progression for 153 mos 12 mos
Current status of tumor Progressive disease No Gd-enhancing lesion Progressive disease
  1. M; male, F; female, GBM; glioblastoma, AO; anaplastic oligoastrocytoma, mos; months, Bx; biopsy, Dx; diagnosis, KPS; Karnofsky performance status, FEBRT; fractionated external beam radiation therapy, Gd; Gadolinium, TMZ; temozolomide, PCV; procarbazine, lomustine and vincristine, CPT-11; irinotecan, BCNU; bischloroethylnitrosourea, CDDP; cisplatin, VP-16; etoposide.